Thanks, CJ, I was unclear on what our interest is in biosimilars. I believe from what you quoted from Dr. Garnick that you're correct on your assessment (won't Dew be surprised).
What you posted tells me nothing about what proprietary technology, if any, PPHM might possess that would enable it to characterize and reverse engineer another company’s protein drug (the skills required to be a serious player in FoB’s). Talk is cheap—I’ll believe that PPHM has a serious FoB program underway when I see some hard evidence. Regards, Dew